• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Broad Institute, Intel partner on of genomic data

Broad Institute, Intel partner on of genomic data

November 21, 2016
CenterWatch Staff

The Broad Institute of MIT and Harvard has announced a $25 million collaboration with Intel to scale researchers' ability to analyze massive amounts of genomic data from diverse sources worldwide.

Through a five-year collaboration, researchers and software engineers at the new Intel-Broad Center for Genomic Data Engineering will build, optimize, and widely share new tools and infrastructure that will help scientists integrate and process genomic data. The project aims to optimize best practices in hardware and software for genome analytics to make it possible to combine and use research data sets that reside on private, public, and hybrid clouds.

The project will enable researchers worldwide to run more data-intensive studies and generate robust results more quickly by accessing data that may have been unavailable to them before.

"The size of genomic datasets doubles about every eight months and, as it does, the challenge of acquiring, processing, storing, and analyzing this information increases as well," said Eric Banks, director of the Data Sciences and Data Engineering group at the Broad Institute. "Working with Intel, we plan to build out solutions that can work across different infrastructures to facilitate efficient processing of these growing data sets, and then make these tools openly available for researchers worldwide. Our work is a step toward building something analogous to a superhighway to connect disparate databases of genomic information for the advancement of research and precision medicine."

Building upon an existing collaboration, the new effort will apply Intel's data analytics and artificial intelligence prowess with Broad's expertise in genomic data generation, health research, and analysis tools toward the goal of building new resources that will promote biomedical discoveries, including those that advance precision medicine.

Under the five-year agreement, the Intel-Broad Center for Genomic Data Engineering will focus on three goals:

  • Overcome the challenge of diverse genomic datasets by optimizing Broad's Genome Analytics Toolkit (GATK) best practices hardware recommendations for genomic workloads for on-premise, public cloud, and hybrid cloud use cases. 
  • Simplify and accelerate the execution of genome analytics by optimizing genomics software tools such as GATK, Cromwell, and GenomicsDB on industry standard Intel-based platforms.
  • Empower users such as healthcare providers, pharmaceutical companies and academic research organizations to collaborate by partnering on workflow execution models across complex and distributed datasets. Achieving this goal will enable secure processing of data across organizations, which can stimulate research and discovery, drug discovery, clinical trial recruitment, and ultimately clinical decision-making across the entire research and discovery ecosystem.

"Intel and Broad share the common vision of harnessing the power of genomic data and making it widely accessible for research around the world to yield important discoveries," said Diane Bryant, executive vice president and general manager of the Data Center Group for Intel Corporation. "We each bring to the collaboration our unique expertise and capabilities.  At Intel, through the use of artificial intelligence, we are confident we can solve the massive data challenges facing the industry."

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing